Alife Health (Alife), the leading technology company building AI tools to advance in-vitro fertilization (IVF), today announced that Fertilidad Integral in Mexico City has become the first international fertility clinic to implement Embryo Predict™, Alife’s AI-powered embryo grading and selection software. The collaboration marks Alife’s first global deployment and a major step forward in bringing advanced, standardized care to patients around the world.

Embryo Predict is a deep learning-based software platform designed to support embryologists in identifying the best embryo for transfer. By integrating directly with the microscope and existing lab infrastructure, the system captures embryo images and automatically generates a personalized AI score, factoring in image-based morphology, day of development, patient age, and egg source, to support consistent and data-informed embryo selection.

“At Fertilidad Integral, we are constantly seeking innovations that can improve outcomes for our patients,” says Jose Alfonso Gutierrez Frusch, M.D., medical director and co-founder of Fertilidad Integral. “By adopting Alife’s Embryo Predict, we’re leveraging the power of AI to bring greater standardization, objectivity and efficiency into our lab workflows. This technology not only helps our clinical team but also empowers patients with personalized reports that help them better understand their journey.”

“We believe deeply in harnessing the best technology in the world to serve our patients,” says Daniel Madero, CEO of Fertilidad Integral. “Embryo Predict empowers our team with objective, data‑driven insights while enhancing transparency and trust with our patients. This collaboration underscores our commitment to excellence and leadership in reproductive care across Latin America.”

With Embryo Predict, Fertilidad Integral is streamlining embryo selection across its laboratory and clinic. The platform’s built-in audit trails and embryo report generation tools also enhance quality control and patient communication, creating a more transparent and supportive experience for families undergoing IVF.

“We’re thrilled to partner with Fertilidad Integral as the first clinic outside the U.S. to adopt Embryo Predict,” says Melissa Teran, CEO and co-founder of Alife Health. “This collaboration represents a major milestone for Alife and reinforces our commitment to expanding access to safe, intelligent fertility care globally. Dr. Gutiérrez Frusch and his team are pioneers in patient-centered care, and we’re honored to support their mission with our technology.”

The joint effort reflects a growing movement toward applying AI to clinical workflows in reproductive medicine, where consistency, time efficiency, and patient trust are critical. Fertilidad Integral’s leadership in adopting Embryo Predict signals a new era of AI-enabled care in Latin America and beyond.